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Abstract: Binge eating disorder (BED) is the most common eating disorder, affecting 
approximately 2% of men and 3.5% of women.  BED has a complex etiology that 
includes both physical and psychological co-morbidities.  Up to 50% of overweight and 
obese people seeking weight loss treatment have BED. Treatment includes 
pharmacological therapy and psychotherapy with the main goals of reducing binge 
frequency and weight reduction. Three categories of medications have been identified for 
the pharmacological treatment of BED:  antidepressants, centrally acting appetite 
suppressants, and anticonvulsants Behavioral weight loss (BWL) includes modest weight 
reduction typically by reducing fat intake, eating regular meals and snacks and increasing 
weekly exercise.  Interpersonal psychotherapy, Cognitive behavioral therapy and 
dialectical behavior therapy are the most successful forms for psychotherapy used to treat 
BED.  In conclusion, BED etiology is multifaceted and successful treatment must address 
the complexities of the disorder.
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Chapter 1:  Background:  Definition of Binge Eating Disorder 
 Binge-eating disorder (BED) was first described as non-purging bulimia nervosa.  
In 1992, it became recognized as a subset of eating disorder not otherwise specified 
(EDNOS). BED is the most common eating disorder, with a lifetime prevalence of 
approximately 2% in men and 3.5% in women (1).  Among individuals seeking treatment 
for obesity, the prevalence estimates range between 15 and 50% (2).   
 BED is defined in the fourth edition (text revision) of the Diagnostic and 
Statistical Manual (DSM-IV-TR) as frequent binge eating episodes, characterized by the 
consumption of a large quantity of food in a discrete period of time, accompanied by a 
subjective sense of loss of control over eating.  Individuals with BED must also 
experience distress about their binge eating, and binge episodes are associated with at 
least three of the following:  eating more rapidly than normal, eating until uncomfortably 
full, eating large amounts when not hungry, eating alone because of embarrassment, and 
feeling disgusted, depressed, or guilty about overeating (2).  BED is unique from bulimia 
nervosa (BN) because it does not include any regular, inappropriate compensatory 
behaviors to avoid weight gain such as self- included vomiting, rigorous exercise, or 
laxative abuse. 
 While the definition of BED does not include a body image related criterion 
similar to those defined for anorexia and bulimia nervosa, higher rates of weight and 
shape concerns are reported in individuals with BED compared to those without (3-4).  
 2 
The term overvaluation describes an excessive influence of shape or weight on an 
individual’s self-evaluation and subsequent feelings of self worth.  The few studies that 
have looked at this in behavior in BED patients noted that the subjects were similar to 
those with BN and AN in their general shape and weight concerns (5-6) and more 
specifically with overvaluation (6).   
 When comparing overweight populations, those with BED have significantly 
greater preoccupation with their shape and weight compared to those without BED (7).  It 
should be noted that concern with shape and weight does not depend on the weight status 
of individuals with BED (5).  A recent study (8) looked at the shape and weight 
overvaluation in 399 patients with BED.  The participants completed the Body Shape 
Questionnaire, the Beck Depression Inventory, and the Rosenberg Self Esteem Scale and 
were grouped as either clinical or subclinical overvaluation.  The subclinical category 
included subjects who reported no influence or, at most, mild influence of shape or 
weight on their self-evaluation.  Fifty-eight percent of participants reported clinical 
overvaluation, and forty two percent reported subclinical overvaluation.  The groups did 
not differ in BMI.  The clinical overvaluation group reported significantly greater levels 
of eating-related psychopathology, body image dissatisfaction, and depression and 
significantly lower self-esteem.  These results suggest that overvaluation of shape and 
weight has clinical significance for both understanding and treating BED.  Patients with 
BED should be assessed for overvaluation and interventions should include the goal of 
challenging and restructuring cognitions based on the exaggerated emphasis of shape and 





THEORIES BEHIND THE BINGE 
 The binge eating disorder behaviors of eating when not experiencing biological 
hunger and feeling disgusted with oneself afterwards, are included in the DSMIV criteria.  
Negative attitudes surrounding eating and body shape, psychiatric comorbidity, GI 
symptoms, and impaired social skills also contribute to the distress associated with the 
binge eating (2).  The mechanisms that drive the binge are still unclear. 
 Many models of BED suggest that the dieting is the main trigger for binge eating.  
In the restraint theory of BED, an obsessive desire to be thin leads to unrealistic dietary 
restraint, resulting in binge eating to make up for the extreme calorie deprivation (9-11).  
A cognitively based variation of extreme dietary restraint is the abstinence violation 
effect.  The binge results when the individual is unable to maintain the very low calorie 
intake.  The diet triggers an all-or-nothing thought process that leads to a feeling of 
failure when unable to maintain perfect dietary restraint.  Such rigid thinking is 
heightened by negative moods, which often lead to poor attempts to control eating and a 
subsequent binge (12).  After the binge episode, the individual returns to the extreme diet 
restriction, and the cycle begins again. 
 Additional theories are founded on the role that affect may play in binge eating.  
Trade off theory (13) suggests that in the presence of negative mood, the binge eating is a 
coping mechanism that allows the individual to substitute the less painful feeling of post-
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binge guilt for the more difficult emotional state of depression that may have preceded 
the binge.  In the short term, the guilt becomes a distraction from the long term suffering 
of the depression (14).  The escape from self awareness model proposes that the act of 
binge eating serves as a way to narrow the focus of the individual’s attention to the 
immediate stimuli provided by the food in an effort to block out and avoid dealing with 
other negative emotions (15-16).  Masking theory (17-18) suggests that instead of 
blocking out negative emotions, binge eating becomes the reason for the negative affect 
that then hides other emotional problems.  The negative emotions get blamed on binge 
eating, which subsequently may be perceived as more controllable and/or tolerable than 
other aspects of one’s life that may be the true cause for the distress.  
 In BED, the presence of negative mood is related to the degree to which 
overeating feels out of control and is experienced as a binge (19).  Individuals with BED 
report greater distress resulting from negative moods, then non-binge eaters (13).  
Women with BED or a consistent binge eating pattern also binge eat when feeling only 
moderately negative (20), and report a more negative mood prior to binge eating than do 
women without BED (21-22).  Individuals with BED eat in response to distress and are 
less aware of their internal hunger cues resulting in food consumption that is not in 
response to physical hunger (23). 
 A recent study looked at the relationship of dietary restriction and mood prior to a 
binge.  In the prospective study (24), 33 females with BED used a handheld computer for 
7 days to record binge behaviors.  The subjects reported 1) emotion before and after a 
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binge, 2) perceived hunger and food intake before binge eating compared to control 
times, and 3) contribution of hunger, emotions, and abstinence violation.   Using a paired 
t-test, mean huger was found to be significantly greater (p < 0.05) at binge precursor 
times (M = 4.06, SD = 1.42) than at non-binge times (M=3.54, SD = 0.85).  Negative 
mood was significantly greater (p < 0.001) prior to binge episode (M= 0.61, SD 0.52) 
compared to non-binge times (M= 0.37, SD = 0.21), and even greater post-binge (M= 
0.91, SD 0.51).  Subjects reported the perceived cause of each binge as 47.7% due to how 
they felt, 17.4% the result of breaking a food rule, 14% to hunger, and the remaining 
20.9% were attributed to unknown causes.  The participants in this study did not report 
dietary restriction as the main trigger for binge episodes.  The subjects did report negative 
mood and affect, as the main contributor to the binge and in the short term did not report 
an improvement in mood immediately following the binge. 
PHYSICAL SYMPTOMS  
Chronic gastrointestinal (GI) disorders are common in obese individuals and correlate 
with an increase in health-care support and a negative impact on quality of life (25).  
Individuals with a higher BMI are more likely to report reflux, symptoms of esophagitis, 
vomiting, abdominal pain, bloating, and diarrhea (26-27).  A ten-pound increase in body 
weight over a ten-year span is associated with the onset of new GI symptoms (28).  When 
compared to controls and non-BED subjects, individuals with BED have greater stomach 
capacity (29-31).  This increased gastric size is associated with lower postprandial satiety 
(32).  A population based survey of 4096 (33) measured GI symptoms, frequency of 
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binge eating episodes, and physical activity.  BED was reported in 6.1% of participants.  
After adjusting for BMI, age, gender, race, diabetes mellitus, socioeconomic status and 
physical activity level, BED was independently associated with the following upper GI 
symptoms:  acid regurgitation, heartburn, dysphasia, bloating, and upper abdominal pain 
(p<0.001).  BED was also associated with the following lower GI symptoms:  diarrhea, 
urgency, constipation, and feeling of anal blockage (p<0.01).  It may be beneficial to 
screen obese patients for BED when individuals present with both lower and upper GI 
symptoms. 
ONSET OF OVERWEIGHT STATUS, DIETING, AND WEIGHT GAIN 
 The development of binge eating in overweight and obese individuals is not well 
understood.  To best treat BED and help prevent additional weight gain the sequence of 
events and the onset of the binge eating must be better understood.  Rigid eating 
behaviors, such as restrictive dieting, are the most common precursors and risk factors in 
the development of eating disorders (34).  The literature suggests that binge eating may 
precede dieting for approximately one-third to one-half of BED patients (35-38).  In 
overweight adults with BED, early onset of overweight is significantly associated with an 
early onset of both binge eating and dieting (37,39).  In some of the current literature, 
researchers use sub-typing to help distinguish the onset of BED in subjects.  The two 
groups include individuals whose dieting precedes their binge eating or diet first (DF) 
and those whose binge behaviors precede dieting or binge first (BF). 
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 A university based outpatient eating disorder program collected data from 98 
adults (80 females and 18 males) with BED (40).  Thirty-five percent reported binge 
behaviors prior dieting while sixty five percent of the participants reported that dieting 
preceded binge eating.  Compared with the diet-first (DF) group, the binge-first (BF) 
group was significantly younger at onset of overweight (DF M=15.8 SD 8.4, BF M=12.4 
SD 6.8, p= 0.05), onset of binge eating (DF M=24.9 SD 10.6, BF M=11.6 SD 5.2, 
p=0.001), and the onset of BED diagnosis (DF M= 25.8 SD 11.3, BF M=17.8 SD 10.5, 
p= 0.02).  The rates of binge-first in this study are higher than typically seen in eating 
disorder etiology and may have implications for new ways to treat BED, different from 
other ED. 
 A retrospective study (41) of 155 women with BED examined the patterns of 
onset in binge behavior in diet-first and binge-first subtypes.  The subjects completed the 
Oxford Risk Factor Interview to assess risk factors present before the onset of binge 
eating.  Eighty one percent of the subjects reported that binging preceded dieting, while 
the remaining 19% reported dieting first.  No significant differences were seen in risk 
factors between the groups.  The BF group had a significantly earlier onset of BED 
compared to the DF group (M= 20.71 SD= 8.48 and M= 25.37 SD= 7.51 p=0.007, 
respectively).  The DF group had significantly higher Eating disorder Examination-
Questionnaire (EDE-Q) scores on a scale from 1 (no importance) to 4 (most important) 
compared to the BF for dietary restraint (BF= 1.93 SD 1.41, DF M=2.71 SD=1.28, 
p=0.006), weight concern (BF M=3.79 SD= 1.39, DF M=4.45 SD=0.92, p=0.003), and 
concern with shape (BF M=4.16 SD=1.39, DF M=4.73 SD=0.99, p=0.037). 
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 A retrospective study (36) of 71 women with BED reported that 38.7 % had 
binged prior to dieting while 48.1% reported dieting preceded the binge behavior, it 
should be noted that 13.2% of the subjects reported binge and diet beginning at the same 
time and were put into the same group.  The age of binge onset was significantly lower in 
the BF group (M=11.8 SD= 6.3) compared to the DF group (M= 25.7 SD= 10.9), 
p=0.0001.  The authors suggested that the results indicate a pattern in the development of 
BED.  Earlier onset is more commonly seen in the BF subset, while later onset is seen 
with the DF group.  The BF pattern may be a tool used to better diagnose or prevent the 
development of BED later in life. 
 A retrospective study (37) of 87 individuals with BED (68 females and 19 males) 
was conducted to determine the order of onset of diet and binge behaviors, the age of 
their first binge, and the age when they met the DSM-IV criteria for BED.  Psychological 
factors were also measured to see if there was a difference between the two groups.  The 
subjects completed the Eating Disorders Examination and the SCID to assess past and 
current co-morbid psychiatric disturbance and the SCID-II to assess Axis II personality 
disturbance.  Forty-five percent of the subjects reported that dieting preceded their first 
binge episode (DF) and 55% reported that binge eating receded their first diet (BF).  
There were significant differences between the two groups for both age of first binge (BF 
M=12.56 SD 7.38, DF M=24.9 SD 11.53, p<0.0001) and age the subjects first met the 
BED criteria (BF M=18.8 SD 10.74, DF M=33.2 SD 11.95, p<0.0001).  The BF group 
also had a history of more psychiatric problems were more likely to have an Axis II 
personality disorder. 
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 A retrospective study (42) collected self-reported onset and timing of overweight 
status, dieting, and binge eating was in 284 adults with BED (211 females and 73 males).  
The subjects were grouped as follows: 63% overweight-first (OF), 21% diet-first (DF) 
and 15.8% binge-first (BF).  The BF group was significantly younger at the age of the 
BED diagnosis (OF M=27.3 SD 8.4, DF M=29.4 SD 12.4, and BF M=19.1 SD 11.9, 
p<0.01).  The BF group reported significantly less dietary restraint than the OF and DF 
groups (OF M=2.27 SD 1.5, DF M=2.3 SD 1.5, BF M=1.7 SD 1.1, p<0.05).   
DIETING AND MENTAL HEALTH STATUS 
 It is well established that dieting is a major risk factor for the development of 
disordered eating (43).  A review by the National Task Force on the Prevention and 
Treatment of Obesity (44) looked at the impact of global weight loss treatment and 
specifically dietary restraint on the development or onset of eating disorders in 
overweight and obese adults.  The review also included the impact of weight cycling on 
overall mental well-being. 
 In 1950, Keys (45) published work that demonstrated the strong relationship 
between dieting, weight loss and a downward spiral that included depression and the 
onset of disordered eating.  In the “Minnesota Starvation Experiment”, 32 healthy men 
reduced their food intake to approximately half of their usual calorie intake for 6 months.  
This severe restriction led to a weight loss of approximately 25% of their body weight.  
The subjects experienced and increase in depression and emotional distress.  Some of the 
men engaged in self-mutilation and others started binge eating.  A 3-month period of re-
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feeding followed the initial 6 months.  Some of the participants continued to binge eat, 
hoard food, and display a preoccupation with food after regaining access to food.  The 
findings of this study in a healthy weight population are often generalized to the 
overweight and obese population.  Current recommendations (46) for weight loss in 
overweight and obese adults suggest a modest weight loss of 10% body weight over 6 
months with a calories deficit of 500-1000 kcal/day resulting 1 to 2 pounds per week.   
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Chapter 2:  Treatment:  Treatment Goals  
 BED is a complex diagnosis that requires long-term treatment.  The main goals of 
treatment include reduction or abstinence of binge eating behaviors and weight loss.  A 
combination of long-term pharmacological and behavioral therapies are recommended. 
PHARMACOLOGICAL TREATMENT 
 Three categories of medications have been identified for the pharmacological 
treatment of BED:  antidepressants, centrally acting appetite suppressants, and 
anticonvulsants (47).  In general, individuals with BED often improve in the short term 
with most interventions and have levels of response have been observed with placebo in 
some studies.  The data from randomized placebo controlled studies must be the focus in 
sorting out the best pharmacological treatment options. 
 Seven obese women (48) with BED, seeking weight loss treatment, completed an 
open-label trial of the sibutramine.  The subjects took 15 mg/day for 12 weeks.  Outcome 
assessments included the number of days with binge episodes per week (DBE), the 
number of binge episodes per week (NBE), the Binge Eating Scale (BES), the Beck 
Depression Inventory, and body weight evaluation.  After 3 months, seven of the subjects 
reported that they were no longer binge eating.  The final DBE (M=0.8 SD 1.9) was 
significantly lower than the initial DBE (M=5.2 SD 1.8), p<0.001.  The final NBE 
(M=1.4 SD 3.5) was significantly lower than the initial value (M=8.2 SD 4.4), p< 0.05.  
The mean weight loss was 4 kg from baseline to the final visit.  Subjects reported having 
dry mouth, constipation, and nausea during the study.  
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 Seven adults (6 females and 1 male) with BED participated in a double-blind 
placebo-controlled crossover study (49).  The ten-week study included two 4-week 
dosing periods with 15mg/d sibutramine or placebo in a random sequence crossover 
design.  The two treatments were separated by a two -week non-treatment washout.  
 Sixty obese adults with BED participated in a randomized, double blind placebo 
controlled study for 12 weeks (50).  Following a 2-week run-in period, subjects received 
either 15mg/day sibutramine (n=30) or placebo (n=30).  Binge frequency, measured as 
the number of days with binge-eating episodes during the past week, and weight loss 
were the main outcome measures.  There was no significant difference in binge frequency 
between the two groups.  The researchers reported a significant weight change between 
the treatment (-7.4 kg) and placebo (1.4 kg) groups, p<0.001.  Subjects in treatment 
group reported dry mouth and constipation. 
 Sixty subjects with BED participated in a randomized, placebo-controlled, 
double-blind, flexible-dose study of the efficacy and safety of fluoxetine (51).     
Participants received fluoxetine, 20 to 80 mg/day (n=30), or placebo (n=30) for six 
weeks.  Subjects in the treatment group started with 20 mg/day for the 3 days.  The 
dosage then increased, as tolerated, to 40 mg/day for 3 days, then to 60 mg/day.  After 2 
weeks at 60 mg/day, the dose was increased to 80mg/day as tolerated.  The main outcome 
measure was number of binge episodes per week.  Changes in body weight and BMI 
were also measured.  Number of binges per week significantly lower in the treatment 
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group (M=1.8 SD 2.9) compared to the placebo group (M=2.7 SD 3.8) p=0.03.  Changes 
in body weight were not significant between groups. 
 Twenty subjects (17 females and 3 males) with BED (52) participated in a double 
blind, placebo-controlled trial of fluvoxamine for 12 weeks.  All participants received one 
week of singe-blind placebo, and were then randomized to flexible dose fluvoxamine 
(titrated up to 150 mg/day) or placebo.  The outcome measures included binge frequency, 
eating concern, shape and weight concern.  The number of days with binges decreased in 
both the placebo group (initial M=20 SD 6.21, final M=7.31 SD 9.31) and the treatment 
group (initial M=14.67 SD 55.68, final M=3.11 SD 4.20).  These differences were not 
statistically significant and there was not a significant difference between the treatment 
and placebo groups.  In fact, there were no significant differences between the treatment 
and placebo for any outcome variables.        
     
 Eighty-five subjects with BED participated in a multicenter placebo-controlled, 
double blind trial of fluvoxamine for 9 weeks (53).  All participants started with a 1-week 
single blind lean-in period.  The treatment group received 50mg/day fluvoxamine for a 
minimum of 3 days.  On day for, the dose was adjusted on an individual basis up to 300 
mg/day.  The primary outcome measure was the frequency of binge eating measured by 
the number of binges per week.  The authors reported that the frequency of binges, 
expressed as mean log ([binges/week])+1), decreased in both groups, but more so in the 
treatment group.  This difference was not statistically significant.  
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 Thirty-four outpatients with BED participated in a 6-week randomized, placebo-
controlled, double blind, flexible-dose study to assess the efficacy of sertraline (54).  The 
main outcome measure was number of binge episodes per week.  Following a single-
blind placebo lead-in period, subjects were assigned to double blind treatment with 
sertaline (n=18) or placebo (n=16).  Subjects took 50mg/day for the first 3 days, then 
dose was adjusted up to as much as 200mg/day.  The mean medication dose in the 
treatment group was 187mg/day.  During the study, the frequency of binges decreased 
significantly in the treatment group (initial M=7.6 SD 4.8 and final M=1.13 SD 1.56) and 
placebo group (initial M=7.2 SD 5.8 and final M=3.85 SD 3.81), p< 0.05. 
 Thirty-eight subjects with BED participated in a 6-week, single-center, parallel 
group, randomized, placebo-controlled, double blind, forced titration, flexible-dose study 
to assess the efficacy of citalopram (55).  The primary measure of efficacy was frequency 
of binge-eating episodes.  Secondary measures included frequency of binge days, BMI, 
and weight. After a week of single-blind placebo, subjects were assigned to treatment 
with citalopram (n=19) or placebo (n=19).  Subjects began treatment with 20 mg/day for 
the first 7 days.  The dosage was then increased, as tolerated, to 40 mg/day for 7 days, 
and then 60 mg/day for the remainder of the study.  The medication could be reduced to a 
minimum of 20 mg/day at any time in response to a subject experiencing intolerable side 
effects.  The average dose was 57.9 mg/day for the citalopram group. .  During the study, 
the frequency of binges episodes decreased significantly in the treatment group (initial 
M=5.2 SD 3.6 and final M=1.7 SD 3.1) and placebo group (initial M=5.7 SD 2.6 and 
final M=3.4 SD 3.0), p< 0.05.  Frequency of binges days decreased significantly in the 
 15 
treatment group (initial M=4.0 SD 1.7 and final M=1.2 SD 2.0) and placebo group (initial 
M=4.0 SD 1.5 and final M=2.8 SD 2.2), p< 0.05.  Changes in BMI and weight were not 
significantly different between the groups.   
 Sixty-one subjects with BED (53 females and 8 males) participated in a 14-week 
randomized, placebo-controlled, double blind, flexible dose study to assess the efficacy 
of topiramate (56).  The primary outcome measure was binge frequency, secondary 
measures included number of binge days per week, BMI and weight.  The initial dose 
was 25 mg/day for the first 3 days.  On day 4, the dose increased to 50 mg/day and then 
to 75 or 100 mg on day 7.  The dose was steadily increased to reach a maximum of 
600mg/day at 10 weeks.  The dose was reduced in subjects that did not tolerate the 
increases.   The efficacy of treatment was determined with a repeated-measures random 
regression analysis comparing the rate of change of binge frequency during the treatment 
period between groups as well as the other outcome measures.  Log transformations were 
used to normalize the data and stabilize the variance.  Subjects in the treatment group had 
a significantly greater rate of reduction in binge frequency compared with the placebo 
group (-0.276 SE 0.077, p< 0.001).  A similar reduction was seen for binge day 
frequency (-0.279 SE 0.070, p<0.002), BMI (-0.540 SE 0.182, p=0.003), and body 
weight change (-3.20 SE 1.15, p=0.005).  This study was followed by an open-label, 42-
week extension study (57) with 31 of subjects to assess the long-term effectiveness and 
tolerability of topiramate.  Subjects were evaluated every 4 weeks.  Baseline for 
treatment group was defined as the week 1 of the controlled study, while the baseline for 
the placebo group was defined as the beginning of the open trial or week 16.  Topiramate 
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was titrated upward from an initial dose of 25 mg/day to a maximum dose of 600 mg/day 
based on subject response and tolerability.  The outcome measures included binge 
frequency, binge day frequency, BMI, weight, and percent and total body fat.  Treatment 
was associated with statistically significant changes from baseline in mean binge 
frequency for all subjects who completed at least 4 weeks (-3.2, p < 0.001) and the 
subjects who completed treatment (n=10, -5.0, p= 0.002).  Binge frequency was also 
significantly decreased in from baseline in the subjects that received treatment during 
both the studies (n=15, -4.0, p<.001) and for subjects that received in only during the 
extension study (n=15, -2.5, p=0.044).  
BEHAVIORAL TREATMENT 
 Behavioral treatments for BED include psychotherapy and weight loss.  
Behavioral weight loss (BWL) includes modest weight reduction typically by reducing 
fat intake, eating regular meals and snacks and increasing weekly exercise.  Interpersonal 
psychotherapy, Cognitive behavioral therapy and dialectical behavior therapy are the 
most successful forms for psychotherapy used to treat BED. 
INTERPERSONAL PSYCHOTHERAPY 
 Interpersonal psychotherapy (IPT) for BED, was created by Wilfley (58-59).  It 
was based on treatment for depression and later adapted to treat bulimia nervosa (60).  
IPT is a three phase manualized treatment.  The first phase is composed of four sessions 
focused on a detailed analysis of the interpersonal context within which the eating 
disorder developed and was maintained.  This leads to a formulation of the current 
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interpersonal problem areas, which then form the focus of the second phase of therapy 
aimed at helping the patient make interpersonal changes in the specific area or areas 
identified.  The final phase includes three sessions that review the patient’s progress and 
explore ways to handle future interpersonal difficulties.  During treatment connections 
are made between interpersonal events and binge eating, but the therapy does not include 
any of the specific behavioral or cognitive outcomes that are part of CBT. 
COGNITIVE BEHAVIORAL THERAPY 
 Weight loss programs for obese individuals with BED that do not focus on 
psychological problems may result in lowered self-esteem and increased negative affect 
(61).  When compared with obese non-binge eaters, obese binge eaters lose significantly 
less weight or rapidly regain it, and have higher rates of treatment drop-out (62).  
Cognitive behavior therapy (CBT) (62) is a broader form of therapy that is made up of 
two major components:  behavioral techniques and cognitive restructuring.  In the 
behavioral part, normalizing of the eating pattern is established and individuals are 
encouraged to moderate overall intake.  In the cognitive part, maladaptive thoughts about 
dieting, shape, weight, and overall self-worth are challenged.   
 Seventy-four obese women (62), 37 with BED and 37 non-binge eaters 
participated in a study that compared the efficacy of CBT with behavioral weight loss 
treatment.  Subjects were randomly assigned to one of the four groups that met for 15 
weekly sessions of 150 minutes each.  The outcome measures included concerns about 
shape, weight and eating, restraint, weight, binge-eating, self-esteem, and depression.  
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The experimental design included a pre- and post-measurement with a 6 month follow-
up.  In the CBT groups, the first stage (6 sessions) focused on identifying and changing 
dysfunctional thoughts about shape, weight, and eating.  The second stage (6 sessions) 
was about teaching cognitive techniques to recognize and challenge negative self-talk and 
thought patterns.  The final stage (3 sessions) focused on maintaining new thought 
patterns and avoid future relapses.  The behavior weight loss group focused on healthy 
eating that included three meals and three snacks daily, reducing fat intake, eating 1500-
1800 kcal/day, regular exercise and becoming more aware of high risk situations that may 
precede a binge.  CBT was more effective in reducing concerns about shape, weight, and 
eating, as well as restraint and in improving self-esteem.  These results were maintained 
at 6-month follow-up.  The behavior weight loss treatment was more effective in 
reducing weight.  Binge eating was reduced with both treatments equally at post-
treatment, but at 6 months, the CBT group had significantly fewer subjects that reported 
binge eating. 
 CBT has been shown to be an effective treatment for BED (63-64) and is 
recommended as the psychological treatment of choice (65).  Yet CBT is underutilized in 
BED treatment and few patients receive any mental health treatment that specifically 
targets the eating disorder (66-69) typically receive treatment for general mental health or 
weight loss (69).  Barriers of widespread use of CBT include few clinicians trained and 
the intensity and cost of the treatment that requires twenty 50-min sessions over 5 months 
(70-71).  To help provide cost-effective delivery of treatment resources, experts have 
called for a “stepped care” approach to the treatment of eating disorders, with less 
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intensive treatments as the first step and more intensive treatments saved for those who 
fail to respond (72).  Short, guided self-help (GSH) approaches based on cognitive 
behavioral principles (CBT-GSH) have been shown to be more effective in treating BED 
(71,73) than behavioral weight loss (BWL). 
 Ninety subjects with BED (73) participated in a randomized clinical trail to assess 
the efficacy of CBT-GSH and BWL compared with a control group.  The three 12-week 
treatment conditions were administered individually following guided self-help protocols.  
Intent-to-treat analyses showed that CBT-GSH had significantly higher remission rates 
compared to BWL and controls.  Weight loss was minimal and was not significantly 
different between treatment groups.   
 Two hundred five subjects with BED (71) participated in a randomized clinical 
trail to assess whether patients with BED require therapy in addition to BWL and whether 
IPT is more effective than either BWL or CBT-GSH.  The three treatments were 
conducted during a 24-week interval.  Participants were followed up at 6-month intervals 
for 2 years after the end of treatment.  The IPT sessions were all individual and subjects 
had a total of 19 sessions during 24 weeks.  The total therapy time was the same for the 
BWL group.  The BWL treatment initially focused on dietary change with a weight loss 
goal of 7% of starting weight.  Participants were asked to reduce fat intake to 25% of 
calories from fat.  Self-monitoring of exercise, fat intake, and calorie intake was the main 
goal of the program.  Subjects were encouraged to exercise 2.5 hours per week.  The 
CBT-GSH group had 10 treatment sessions.  Participants were assessed for general 
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psychopathology (SCID-I), personality disorders (SCID-II), and eating disorder 
psychopathology (EDE).  At 2-year follow-up, both IPT and CBT-GSH resulted in 
greater remission from binge eating than BWL (p<0.05, odds ratios: BWL vs CBT-GSH, 
2.3; BWL vs IPT, 2.6; and CBT-GSH vs IPT, 1.2).  Self-esteem (p<0.05) and global 
Eating Disorder Examination (p<0.05) scores were moderators of the treatment outcome.  
IPT and CBT-GSH were significantly more effective than BWL in eliminating binge 
eating after 2 years.  Guided self-help based on CBT is a first-line treatment option for 
patients with BED, with IPT or full CBT used for patients with low self-esteem and high 
eating disorder psychopathology.  
 One hundred twenty three subjects (74), 59 with BED participated in randomized, 
clinical trail to evaluate whether a CBT-GSH delivered in 8 sessions in a health 
maintenance organization (HMO) setting over a 12-week period was more effective than 
treatment at usual (TAU).  TAU includes treatment of general mental health conditions 
and weight loss, not specifically the eating disorder pathology.  Baseline, post-treatment, 
and 6- and 12-month follow-up data were used in intent-to-treat analyses.  At 12-month 
follow-up, CBT-GSH resulted in greater abstinence from binge eating (64.2%) than TAU 
(44.6%), measured by the EDE scores.  Secondary outcomes reflected greater 
improvements in the CBT-GSH group in dietary restraint (d=0.30), eating, shape, and 
weight concern (ds= 0.54, 1.10, 0.49, respectively).  There was no difference in weight 




 The primary goals of CBT-GSH are to develop a regular pattern of moderate 
eating using self-monitoring, self-control strategies, and problem-solving.  Relapse 
prevention is emphasized to promote maintenance of behavioral change.  The primary 
role of the therapist is to explain the rational for the use of the self-help manual, generate 
a reasonable expectancy for a successful outcome, and to motivate the patient to focus on 
using the manual.  Individuals with BED frequently suffer from multiple problems in 
addition to binge eating including, high levels of eating disorder psychopathology 
(unhealthy restraint and eating patterns, eating concerns, and overvalued ideas regarding 
weight and shape) and psychological distress (depression and low self-esteem) (75-76).   
 Etiological models highlight a variety of cognitive, behavioral, interpersonal, and 
affective risk factors implicated in binge-eating episodes (15,77).  Cognitive risk factors 
include the internalization of the “thin ideal”, divided thought patterns pertaining to food 
and eating, body dissatisfaction, and unrealistic standards and expectations of oneself.  
Behavioral risks involve food restrictions and restraints.  Interpersonal factors include 
isolation, interpersonal skill deficits, and dissatisfaction with interpersonal relations.  
Affective risk factors include low self-esteem, anxiety, and dysphoria.  The roles of 
restrained eating and negative affect are central in the conceptual models of treatment. 
 CBT (78) focuses on these behavioral and cognitive factors by prescribing regular 
meals and snacks in an effort to establish normal eating patterns and decrease urges to 
binge, encouraging exposure to “feared” foods, and changing distorted thinking about 
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weight, body image, and food.  In contrast, interpersonal theories (such as IPT) describe 
the binge behavior in the context of being symptomatic of disturbances in interpersonal 
functioning.  The treatment focuses on recognizing and problem-solving interpersonal 
difficulties involved in grief, disputes, role transitions, or interpersonal deficits. 
 Individuals who binge may have trouble with emotion regulation.  Binge eating 
can be used as a fast way to numb emotions that are painful, rather than adapt to the 
emotion (79).  During a binge episode, attention is focused, and thoughts are directed 
away from the true meaning behind an emotional response and instead directed on 
immediate food-related issues.  The binge functions as a way to cope with unpleasant 
emotions and escape emotional distress when the individual is unable to regulate their 
emotions in a healthy way (78).  
DIALECTICAL BEHAVIOR THERAPY  
 Dialectical behavior therapy (DBT) can best be described as a combination of 
CBT and the Eastern Zen practices (80) of observation, mindfulness, and avoidance of 
judgment.  It is the balance between finding a strategy for change while simultaneously 
accepting that change must happen.  The behavioral portion of DBT includes a structured 
contract or set of agreements threat both the client and therapist agree to.  DBT is the 
empirically validated treatment of choice for people with borderline personality disorder.  
It is a long-term treatment aimed at decreasing behaviors that are life threatening and 
quality-of-life impairing.  DBT primarily treats adaptive affect regulation and may be 
helpful in treating binge eating (78). 
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 CBT and IPT have shown to be unable to help as many as 50% of individuals 
with eating disorders (81).  One theory is that individuals that don’t respond to CBT or 
IPT are not early rapid responders to treatment (82-83), have more severe eating disorder 
symptoms, are more impulsive (84), report increased negative mood,(85) or have other 
mental health co-morbidities.  DBT may be the treatment approach that helps this sub-set 
of individuals with BED.  Standard DBT involves group skills training, individual 
psychotherapy, a therapist consultation team, and access to 24-hr telephone coaching.   
 Forty-four women with BED (86) were randomly assigned to group DBT or a 
wait list control condition to evaluate the use of DBT adapted for BED.  Baseline and 
post-treatment measures included the EDE, weight, mood, and affect regulation.  
Subjects in the treatment group had significantly lower number of binge days and binge 
episodes (p<0.01) and significantly lower scores for weight, shape, and eating concerns 
(p<0.05).  There were no significant differences between groups on dietary restraint.  
Eighteen women in the treatment group were assessed at the 3- and 6-month follow-ups.  
At 3-month 67% and at 6-month 56% reported abstaining from binge behaviors.  At 6-
month follow-up, the 89% continued to practice skills taught during treatment, practicing 
an average of 3.6 different skills per week on an average of 4 days per week. 
 In a randomized, controlled trail, 101 subjects with BED (87) were assigned to 20 
sessions of group therapy: DBT for binge eating disorder (DBT-BED) or active 
comparison group therapy (ACGT).  Assessments of eating behaviors and emotion 
regulation were administered at baseline, post-treatment, and 3-, 6-, and 12-months 
 24 
following treatment.  The DBT-BED group had a significantly lower dropout rate (4%) 
than the ACGT group (33.3%).  Linear Mixed Models showed post-treatment binge 
abstinence and reductions in binge frequency were achieved more quickly for DBT-BED 
(64%) than ACGT (36%).  There were no significant differences reported at the follow-
up assessments.  At 12-month follow-up binge abstinence rate = 64% for DBT-BED and 
56% for ACGT.  There were no significant changes on emotion regulation.   
COMBINATION TREATMENT 
 Eighty obese subjects with BED (88), were randomly assigned to either CBT or 
BWL groups that participated in 16 weekly treatments and 6 monthly follow-up sessions.  
Binge eating, general psychopathology, and BMI were assessed at baseline, post-
treatment, and 12-month follow-up.  At the end of treatment, both groups had significant 
reductions in binge episodes and frequency.  The CBT treatment group had a faster 
improvement on binge behaviors, while the BWL group had faster reduction in BMI.   At 
12-month follow-up, there were no significant differences between the treatment groups. 
 One hundred sixteen subjects with BED (89) participated in a 20-week behavioral 
weight control treatment study designed to evaluate the added benefit of two adjunctive 
interventions, individual CBT and fluoxetine, in 16 group sessions.  Subjects were 
randomly assigned to receive CBT + fluxetine, CBT + placebo, fluoxetine, or placebo in 
a two-by-two factorial design.  Outcome measures assessed at the end of treatment 
included binge frequency, weight, and measures of eating-related and general 
psychopathology.  All subjects reduced binge eating and had improvements in both 
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general and eating-related psychopathology.  Subjects that received CBT had 
significantly lower binge frequency (p<0.001) and increased binge abstinence (p<0.001) 
compared with subjects that did not receive CBT.  Fluoxetine treatment was associated 
with significantly greater reduction in depressive symptoms compared with placebo 
(p<0.05). 
 One hundred sixty-two subjects with BED (58), were randomly assigned to 20 
weekly sessions of either group CBT or group IPT.  Assessments of binge eating and 
related eating disorder psychopathology, general psychological functioning, and weight 
were obtained at baseline, post-treatment, and at 4-month intervals up to 12-months 
following treatment.  There were no significant differences in binge-eating recovery rates 
for both groups post-treatment (CBT= 79%, IPT = 73%) and at 1-year follow-up (CBT = 
59%, IPT = 62%).  Binge eating increased from post-treatment to follow-up, but 
remained significantly lower than baseline measures.  Across treatments, patients had 
similar significant reductions in associated eating disorder symptoms.  Dietary restraint 




Chapter 3:  Recommendations:  Meta-analysis  
 
 A 2010 meta-analysis by Vocks et. al (90) compared the effectiveness of the 
available psychological, pharmacological, and weight-loss treatments of BED with regard 
to the major outcomes of symptomatology concerning BE behavior, body weight, 
restrained eating, concerns about eating, weight and shape, depression, and dropout rates.  
The meta-analysis included 38 studies with 1973 participants.  Effect sizes, odds ratios, 
and simple rates were integrated in fixed and random (mixed) effects categorical models.  
The results of the meta-analysis indicated that from randomized controlled trials, 
psychotherapy and structured self-help, both based on cognitive behavioral interventions, 
were found to have large effects on the reduction of binge eating.  The randomized 
controlled pharmacotherapy trials, mainly comprised on anti-depressants, revealed 
medium effects for the reduction of binge eating.  Uncontrolled studies on weight-loss 
treatments showed moderate reductions of binge eating.  Combination treatments did not 
result in higher effects compared with single-treatment regiments.  Except for weight-loss 
treatment, none of the interventions resulted in considerable weight reduction.  In 
conclusion, psychotherapy and structured self-help, both based on cognitive-behavioral 
therapy are recommended as the first-line treatments. 
FUTURE DIRECTIONS 
 The public health sector has responded well to the obesity problem in America, 
sending out a clear message that a change in daily habits will promote weight loss and 
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maintain a healthy weight.  For most people, eating less and moving more are attainable 
goals.  For the overweight and obese individuals with BED, this message is not enough.  
The subset of the population that also suffers from the mental health co-morbidities 
common in BED, may require psychotherapy and pharmacological intervention.  This 
gap in the treatment protocol for weight reduction in the overweight and obese, may be 
reinforcing the restricting eating patterns and binge behaviors that lead to weight gain.  
To best help the BED population, it would be beneficial to screen for both the 
physiological and psychological symptoms in the physicians office to help identify the 
disordered eating behavior.  The message of wellness should focus on small changes over 
time that lead to long-term weight reduction and relapse prevention. 
CONCLUSION 
The high prevalence of BED in the overweight and obese population seeking weight loss 
treatment illuminates the need for a change in weight loss treatment.  BED is a complex 
diagnosis that does not have a one size fits all treatment protocol.  This disordered eating 
behavior cannot be treated with diet and exercise alone.  The high rate of placebo 
response to drug-therapy is an important part of the puzzle.  The mental health status of 
the individual should be assessed.  A treatment team that includes a physician, therapist, 
and dietitian will help to increase successful weight loss and prevent relapse.  The 
underlying goals of abstinence from binge behaviors and sustained weight loss will 
ultimately result in an increased quality of life for individuals with BED.  Taken together, 
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